Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
UCB
Biotech
Biogen, UCB report phase 3 lupus win after failing earlier trial
Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive data.
Nick Paul Taylor
Sep 24, 2024 6:00am
100 days with John Crowley: Behind BIO’s new structure & vision
Jun 25, 2024 9:05am
Veeva, UCB link to leverage digital tools in clinical trials
May 24, 2023 3:25pm
Praxis ends year on high with $100M biobucks UCB deal
Dec 14, 2022 5:29am
Alchemab CEO resigns citing 'personal reasons'—Chutes & Ladders
May 27, 2022 9:30am
UCB races to regulators after $2B rare disease bet delivers data
Feb 4, 2022 8:25am